Guangdong Hengrui Pharmaceutical Co., Ltd

This early-stage trial is testing a new drug called SHR-2173 for people with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study will enroll 10 adults to check the drug's safety and how well it works. Particip…

This Phase 2 trial tests an investigational drug called SHR-2173 in 84 adults with primary IgA nephropathy, a kidney disease. Participants receive either a high, medium, or low dose of SHR-2173 or a placebo for 48 weeks. The main goal is to see if the drug reduces protein in the …

This Phase 2 clinical trial is testing an investigational drug called SHR-2173 in about 248 adults with active systemic lupus erythematosus (SLE). Participants will receive either the drug or a placebo for 24 weeks, with follow-up. The main goal is to see if SHR-2173 can reduce l…

This study tests an experimental drug called SHR-1905 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Half will get the drug, half a placebo, and neither they nor their doctors will know who got what. The main goal is to see if the drug can reduce eczema severity…

This phase 3 trial tests an experimental drug called SHR-1819 in about 200 teenagers aged 12 to 17 with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo injection. The study measures how well the drug clears skin rashes and reduces …

This Phase 2 trial tests an experimental drug called SHR-2173 in 75 adults with primary membranous nephropathy, a kidney condition that can lead to kidney failure. The drug is given as an injection over several doses. Researchers are checking if it is safe and can help control th…

This study tests a new drug called HRS-9813 in 270 adults with pulmonary fibrosis (IPF or PPF), a condition where lung tissue becomes scarred and breathing gets harder. The trial compares the drug to a placebo to see if it improves lung function and is safe. Participants take the…

This phase 2 study tests a new drug called SHR-1703, given as multiple injections under the skin, for people with eosinophilic asthma. The goal is to see if it is safe and helps control asthma over the long term. About 200 adults will take part, and researchers will monitor side …

This study tests a new medicine called SHR-1703 to see if it can reduce asthma attacks in people with eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. About 400 participants aged 12 and older who already use daily inhaled steroids and othe…

This study tests a new drug, SHR-1703, for people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that causes inflammation in blood vessels. The trial will include 166 adults who have not responded well to standard treatments. The goal is to see if SHR-1…

This study tests an experimental drug called SHR-2173 for people with active lupus nephritis, a kidney complication of lupus. About 51 adults will receive either the drug or a placebo to see if it improves kidney function and reduces protein in urine. The goal is to control the d…

This study tests an experimental injection called SHR-1905 in 280 adults with chronic sinusitis and nasal polyps. Participants must have moderate-to-severe symptoms despite standard nasal sprays. The goal is to see if the drug shrinks polyps and improves congestion over 24 weeks …

This phase 3 trial tests a new drug called SHR-1905 for adults with severe asthma that is not well controlled by current treatments. The study will compare the drug to a placebo to see if it reduces asthma attacks and improves lung function. About 408 participants will take part …

This study tests an injection called SHR-1819 to see if it can safely reduce the intense itching caused by prurigo nodularis, a chronic skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their wor…

This early-stage study tests a new inhaled drug called HRS-9821 in 160 people. First, healthy volunteers get a single dose to check safety. Then, people with COPD receive multiple doses. The main goal is to see what side effects occur and how the drug moves through the body. This…

This study tests an injection called SHR-1819 in 100 adults with seasonal allergic rhinitis (hay fever). Participants will receive either the drug or a placebo to see if it reduces daily nasal symptoms like sneezing and stuffiness. The trial is double-blind, meaning neither patie…

This early-stage trial is testing a new drug called HRS-9813 in 20 healthy volunteers to see how it interacts with two standard treatments for pulmonary fibrosis (lung scarring): pirfenidone and nintedanib. The goal is to measure drug levels in the blood and check for side effect…